Abstract: The present disclosure relates to methods, compositions, and kits for isolating target nucleic acids below a target size from a sample comprising nucleic acid components. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions, at least one solid phase medium, and at least one buffer. Some embodiments provide a kit comprising one or more ATPS compositions, at least one solid phase medium, and at least one buffer. Other embodiments provide methods for diagnosing a disease or condition using the methods described herein.

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: Devices and methods are provided for the detection of CSF in a biological sample.

Abstract: In various embodiments methods and devices are provided for the detection and/or quantification of an analyte. In certain embodiments a device is provided comprising an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase where, in use, said first phase solution becomes a leading phase and said second phase solution becomes a lagging phase; a lateral-flow assay (LFA); and a probe and/or a development reagent, where in use, said probe associates with said first phase solution in said leading phase of said ATPS and/or said development reagent associates with said second phase solution in said lagging phase of said ATPS. In certain embodiments a “one-pot” system of purifying and amplifying a nucleic acid is provided utilizing, e.g., an ATPS and isothermal amplification reagents.

Abstract: In various embodiments methods to improve the detection of a lateral-flow immunoassay for the sensitive detection of the SARS-CoV-2 nucleocapsid protein or other analytes, as well as devices that incorporate those methods are provided.

Abstract: Devices and methods are provided for the detection of CSF in a biological sample.

Abstract: In various embodiments methods and devices are provided for the detection and/or quantification of an analyte. In certain embodiments a device is provided comprising an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase where, in use, said first phase solution becomes a leading phase and said second phase solution becomes a lagging phase; a lateral-flow assay (LFA); and a probe and/or a development reagent, where in use, said probe associates with said first phase solution in said leading phase of said ATPS and/or said development reagent associates with said second phase solution in said lagging phase of said ATPS. In certain embodiments a “one-pot” system of purifying and amplifying a nucleic acid is provided utilizing, e.g., an ATPS and isothermal amplification reagents.